Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy - 05/04/18
, Cameron J. Turtle a, bCet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
T-cells engineered to express CD19-specific chimeric antigen receptors (CD19 CAR-T cells) can achieve high response rates in patients with refractory/relapsed (R/R) CD19+ hematologic malignancies. Nonetheless, the efficacy of CD19-specific CAR-T cell therapy can be offset by significant toxicities, such as cytokine release syndrome (CRS) and neurotoxicity. In this report of our presentation at the 2018 Second French International Symposium on CAR-T cells (CAR-T day), we describe the clinical presentations of CRS and neurotoxicity in a cohort of 133 adults treated with CD19 CAR-T cells at the Fred Hutchinson Cancer Research Center, and provide insights into the mechanisms contributing to these toxicities.
Le texte complet de cet article est disponible en PDF.Keywords : Review, Chimeric antigen receptor therapy, Hematological malignancies, Adoptive t-cell therapy, Cytokine release syndrome, Neurotoxicity
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?